News
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...
Clinical Trials Arena on MSN21h
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trialUS-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback